**Core Concept**
Mifepristone is a progesterone receptor antagonist used in the management of uterine fibroids. The underlying principle being tested is the pharmacological action of mifepristone on fibroid growth and development, which is influenced by hormonal regulation.

**Why the Correct Answer is Right**
Mifepristone exerts its effects by competitively binding to progesterone receptors in the uterus, thereby inhibiting the action of progesterone on fibroid growth. Progesterone is essential for maintaining the growth and differentiation of fibroid cells. By blocking progesterone receptors, mifepristone reduces fibroid cell proliferation and leads to shrinkage of the fibroids. This mechanism is particularly effective in reducing symptoms associated with uterine fibroids, such as heavy menstrual bleeding and pelvic pressure.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because mifepristone is not a progesterone agonist, and its mechanism of action does not involve stimulating fibroid growth.

**Option B:** This option is incorrect because mifepristone is not an estrogen receptor antagonist, and its effects on fibroids are not primarily mediated through estrogen receptors.

**Option C:** This option is incorrect because mifepristone does not cause an increase in fibroid size or symptoms; rather, it leads to shrinkage and reduction of symptoms.

**Clinical Pearl / High-Yield Fact**
It is essential to note that mifepristone is not a treatment for all types of uterine fibroids and may not be effective in cases where fibroids are driven by other hormonal or genetic mechanisms.

**Correct Answer:** B. Shrinkage